| Literature DB >> 29988504 |
Henan Li1, Hua Gao1, Han Meng1, Qi Wang1, Shuguang Li1, Hongbin Chen1, Yongjun Li2, Hui Wang1.
Abstract
Metagenomic next-generation sequencing (mNGS) is a comprehensive approach for sequence-based identification of pathogenic microbes. However, reports on the use of mNGS in pulmonary infection applied to lung biopsy tissues remain scarce. In this study, we applied mNGS to detect the presence of pathogenic microbes in lung biopsy tissues from 20 patients with pulmonary disorders indicating possible infection. We applied a new data management for identifying pathogen species based on mNGS data. We determined the thresholds for the unique reads and relative abundance required to identify the infectious pathogens. Potential pathogens of pulmonary infections in 15 patients were identified by mNGS. The comparison between mNGS and culture method resulted that the sensitivity and specificity were 100.0% (95% CI: 31.0-100.0%) and 76.5% (95% CI: 49.8-92.2%) for bacteria, 57.1% (95% CI: 20.2-88.2%) and 61.5% (95% CI: 32.2-84.9%) for fungi. The positive predictive value (PPV) (42.9% for bacteria, 44.4% for fungi) was much lower than negative predictive value (NPV) (100% for bacteria, 72.7% for fungi) in mNGS vs. culture method. The mNGS showed the highest specificity (100.0 and 94.1%) and PPV (100.0 and 75.0%) in the evaluation of fungi and MTBC respectively, when compared with histopathology method. The study indicated that mNGS of lung biopsy tissues can be used to detect the presence (or absence) of pulmonary pathogens in patients, with potential benefits in speed and sensitivity. However, accurate data management and interpretation of mNGS are required, and should be combined with observations of clinical manifestations and conventional laboratory-based diagnostic methods.Entities:
Keywords: clinical diagnosis; data management; lung biopsy tissues; metagenomic next-generation sequencing (mNGS); pulmonary infection
Mesh:
Year: 2018 PMID: 29988504 PMCID: PMC6026637 DOI: 10.3389/fcimb.2018.00205
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Pulmonary disorders patients for metagenomic next-generation sequencing and conventional laboratory-based diagnostic testing.
| P1 | Male | 26 | AML; allo-HSCT | Fungal infections | Yes | Fungal nonseptatehypha (90 degrees) | Negative | Fungal hypha (probable | ND | Fungal infection |
| P2 | Female | 43 | Uterine leiomyoma (postoperative) | Pulmonary occupying lesion | No | Fungal hypha | Negative | Several acid-fast bacteria | MTBC positive by quantitative real-time PCR | MTBC infection, bacterial infection |
| P3 | Female | 54 | ALL | Pulmonary infection | Yes | Fungal nonseptatehypha (90 degrees) | Negative | Fungal hypha | ND | Fungal infection |
| P4 | Male | 51 | Type 2 diabetes mellitus | Pulmonary tuberculosis | No | Acid-fast bacteria | Negative | Single suspicious acid-fast bacterium | MTBC positive by GeneXpert | MTBC infection |
| P5 | Male | 60 | Type 2 diabetes mellitus; excision of thyroid adenoma | Pulmonary tuberculosis | No | Acid-fast bacteria | Negative | Acid-fast bacteria | ND | MTBC infection |
| P6 | Female | 49 | None | Lung cancer (adenocarcinoma) | No | Gram-negative bacilli | Negative | Adenocarcinoma | MTBC negative by GeneXpert | Noninfectious |
| P7 | Female | 61 | None | Pulmonary inflammatory lesions; Pulmonary occupying lesion | No | Negative | Negative | Chronic nonspecific inflammatory | ND | Noninfectious |
| P8 | Female | 40 | None | Pulmonary occupying lesion, pulmonary infection | No | Negative | Negative | Scattered lymphocyte infiltration | ND | Noninfectious |
| P9 | Female | 24 | ALL; allo-HSCT | Pneumonia (coinfection, fungi confirmed) | Yes | Negative | Negative | Fungal hypha | ND | Fungal infection |
| P10 | Male | 49 | AML; allo-HSCT | Fungal infections | Yes | Negative | Negative | Fungal hypha | ND | Fungal infection |
| P11 | Male | 58 | Chronic myelogenous leukemia; COPD | Lung squamous cell carcinoma | Yes | Negative | Negative | Probable squamous cell carcinoma | ND | Noninfectious |
| P12 | Male | 66 | COPD | Lung cancer | No | Negative | Negative | Probable a malignant tumor with epithelioid differentiation | MTBC negative by GeneXpert | Noninfectious |
| P13 | Female | 39 | AML; allo-HSCT | Fungal infections | Yes | Negative | Fungal hypha | MTBC negative by quantitative real-time PCR | Fungal infection | |
| P14 | Female | 43 | Chronic hepatitis B virus hepatitis | Pulmonary tuberculosis (high probability) | No | Negative | Scattered lymphocyte infiltration; granuloma formation | MTBC positive by GeneXpert | MTBC infection | |
| P15 | Male | 54 | Hypertension | Pulmonary inflammatory lesions | No | Fungal hypha | Chronic nonspecific suppurative inflammation | ND | Bacterial infection | |
| P16 | Male | 29 | AML; allo-HSCT | Lung infection (fungi, bacteria) | Yes | Fungal hypha | Fungal components (probable | ND | Fungal infection, bacterial infection | |
| P17 | Female | 73 | Coronary atherosclerosis | Fungal infections | No | Fungal hypha | Fungal components | ND | Fungal infection, bacterial infection | |
| P18 | Female | 39 | None | Fungal infection | No | Fungal hypha | Fungal components | ND | Fungal infection, bacterial infection | |
| P19 | Male | 46 | None | Fungal infections | No | Gram-negative bacilli | Fungal hypha | ND | Fungal infection, bacterial infection | |
| P20 | Male | 6 | ALL; post-right lower lung resection | Pulmonary infection | Yes | Fungal septatehypha | Fungal hypha (probable filamentous fungi except for | MTBC negative by quantitative real-time PCR | Bacterial infection |
AML, Acute myeloid leukemia; ALL, Acute lymphocytic leukemia; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; COPD, chronic obstructive pulmonary disease; MTBC, Mycobacterium tuberculosis complex; PCR, polymerase chain reaction; ND, no data.
Figure 1Heat maps reporting the relative abundance at the genus level of the 10 most abundant bacterial species (A) and fungal species (B) identified by metagenomic next-generation sequencing (mNGS) in 20 lung biopsy tissues. The infectious bacteria or fungi were marked with black horizontal lines if >30% relative abundance at the genus level, or marked with black scatter spots if included at least 50 unique reads from culture and/or histopathological examination positive bacteria or fungi.
Figure 2Optimal thresholds for infectious fungi identification by metagenomic next-generation sequencing (mNGS). The fungal species which contained the highest relative abundance and maximum number of unique reads in each sample were selected, and the relative abundance and unique reads were shown in (A). The red dots indicated fungi identified by mNGS in samples which were consistent with culture results at the genus or species level. Blue dots indicated species identified by mNGS in samples which showed fungal hypha by histopathological examination. Black dots indicated species identified by mNGS in samples which had negative results of fungi by conventional culture and/or histopathology methods. Sensitivity and specificity with 95% confidence intervals were calculated under different threshold (B).
Metagenomic next-generation sequencing results of 20 lung biopsy samples.
| P1 | Negative | 151 | 0.0425 | 1.31 | Fungal infection | |
| P2 | Negative | 1 | 0.038 | 1 | MTBC infection, bacterial infection | |
| Negative | 1,500 | 3.1 | 1 | |||
| P3 | Negative | 743 | 0.21 | 1 | Fungal infection | |
| P4 | Negative | 5 | 0.021 | 1 | MTBC infection | |
| P5 | Negative | 5 | 0.9 | 1 | MTBC infection | |
| P6 | Negative | Negative | Noninfectious | |||
| P7 | Negative | Negative | Noninfectious | |||
| P8 | Negative | Negative | Noninfectious | |||
| P9 | Negative | 21,548 | 0.14 | 1 | Fungal infection | |
| P10 | Negative | 132 | 0.073 | 1 | Fungal infection | |
| P11 | Negative | Negative | Noninfectious | |||
| P12 | Negative | 453 | 3.5 | 1 | Noninfectious | |
| P13 | 2,187 | 0.27 | 1 | Fungal infection | ||
| 31 | 0.011 | 1 | ||||
| P14 | 1,425,089 | 50 | 75 | |||
| 0 (23 from MTBC) | 0.027 | 1.5 | MTBC infection | |||
| P15 | 1 | 0.011 | 1.3 | |||
| 1 | 0.00041 | 1.7 | ||||
| 69 | 0.2478 | 1 | Bacterial infection | |||
| 57 | 0.1153 | 1 | ||||
| P16 | 85 | 0.0106 | 9 | Fungal infection, bacterial infection | ||
| 183 | 0.0036 | 36.35 | ||||
| 660 | 1.6 | 1.1 | ||||
| P17 | 185 | 0.0343 | 2.91 | Fungal infection, bacterial infection | ||
| 190 | 0.0033 | 39.42 | ||||
| 242 | 0.66 | 1 | ||||
| P18 | 4,508 | 1.1149 | 1.01 | Fungal infection, bacterial infection | ||
| 378,078 | 84 | 12 | ||||
| P19 | 227,748 | 82 | 8.1 | Fungal infection, bacterial infection | ||
| 73,043 | 32 | 1.2 | ||||
| P20 | 6 | 0.0036 | 1.1 | |||
| 4,247 | 15 | 3.9 | Bacterial infection | |||
Inferred pathogen combined with culture and/or histopathological examination results.
Rare pathogen in pulmonary infection, which was not interpreted as pathogen.
Obligate anaerobe.
Below the thresholds.
The detail information of samples with conflicting results.
| P2 | Fungal hypha | Negative | Several acid-fast bacteria | MTBC | MTBC positive by quantitative real-time PCR WBC 14.80 × 10∧9/L (↑) | Pulmonary occupying lesion |
| P6 | Gram-negative bacilli | Negative | Adenocarcinoma | Negative | MTBC negative by GeneXpert CRP 1.5mg/L PCT < 0.02ng/ml | Lung cancer (adenocarcinoma) |
| P14 | Negative | Scattered lymphocyte infiltration; granuloma formation | MTBC | MTBC positive by GeneXpert | Pulmonary tuberculosis (high probability) | |
| P20 | Fungal septatehypha | Fungal hypha (probable filamentous fungi except for | WBC 11.06 × 10∧9/L (↑) CRP 16.62 mg/L (↑) MTBC negative by quantitative real-time PCR | Pulmonary infection |
MTBC, Mycobacterium tuberculosis complex; PCR, polymerase chain reaction; WBC, white blood cell count; CRP, C-reactive protein; PCT, procalcitonin.
Up arrow (↑) indicated that the result was higher than normal reference range.
Figure 3Testing of lung biopsy tissues from 20 patients with pulmonary disorders by conventional laboratory-based diagnostic methods and metagenomic next-generation sequencing (mNGS). MTBC, Mycobacterium tuberculosis complex; PCR, polymerase chain reaction; TAT, turn-around time.
Diagnostic performance of metagenomic next-generation sequencing (mNGS) when compared with conventional laboratory-based diagnostic methods in the detection of bacteria, fungi, and Mycobacterium tuberculosis complex (MTBC).
| Bacteria | Smear | 50.0 (2.7–97.3) | 66.7 (41.2–85.6) | 14.3 (0.8–58.0) | 92.3 (62.1–99.6) |
| Culture | 100.0 (31.0–100.0) | 76.5 (49.8–92.2) | 42.9 (11.8–79.8) | 100.0 (71.7–100) | |
| Fungi | Smear | 62.5 (25.9–89.8) | 66.7 (35.4–88.7) | 55.6 (22.7–84.7) | 72.7 (39.3–92.7) |
| Culture | 57.1 (20.2–88.2) | 61.5 (32.2–84.9) | 44.4 (15.3–77.4) | 72.7 (39.3–92.7) | |
| Histopathology | 90.0 (54.1–99.5) | 100.0 (65.6–100.0) | 100.0 (62.9–100.0) | 90.9 (57.1–99.5) | |
| MTBC | Smear | 100.0 (19.8–100.0) | 88.9 (63.9–98.1) | 50.0 (9.2–90.8) | 100.0 (76.0–100.0) |
| Histopathology | 100.0 (31.0–100.0) | 94.1 (69.2–99.7) | 75.0 (21.9–98.7) | 100.0 (75.9–100.0) | |
PPV, positive predictive value; NPV, negative predictive value; CI: Confident Intervals.